These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 30866124)

  • 1. Why plasma-derived factor VIII?
    Aledort L; Carpenter SL; Cuker A; Kulkarni R; Recht M; Young G; Leissinger C
    Haemophilia; 2019 May; 25(3):e183-e185. PubMed ID: 30866124
    [No Abstract]   [Full Text] [Related]  

  • 2. Rapid and sustained immune tolerance to inhibitors induced by a plasma-derived, VWF-containing FVIII concentrate.
    Santagostino E; Rangarajan S; Oldenburg J; Peiró-Jordan R; Jiménez-Yuste V
    Haemophilia; 2019 Mar; 25(2):e110-e113. PubMed ID: 30786119
    [No Abstract]   [Full Text] [Related]  

  • 3. Preservation of factor VIII activity in plasma by different freezing techniques, as determined with a chromogenic microtray assay.
    Vaara I; Jonsson M
    Scand J Clin Lab Invest; 1989 Apr; 49(2):161-4. PubMed ID: 2520368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reagent substitutions in the Centers for Disease Control and Prevention Nijmegen-Bethesda assay for factor VIII inhibitors.
    Miller CH; Payne AB; Driggers J; Ellingsen D; Boylan B; Bean CJ
    Haemophilia; 2018 May; 24(3):e116-e119. PubMed ID: 29573516
    [No Abstract]   [Full Text] [Related]  

  • 5. Issues with the assay of factor VIII activity in plasma and factor VIII concentrates.
    Lundblad RL; Kingdon HS; Mann KG; White GC
    Thromb Haemost; 2000 Dec; 84(6):942-8. PubMed ID: 11154139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factor VIII (antihemophilic globulin).
    Aronson DL
    Semin Thromb Hemost; 1979; 6(1):12-27. PubMed ID: 390712
    [No Abstract]   [Full Text] [Related]  

  • 7. [Experimental quality assessment of APTT-control reagent kits in the study of plasma with varying Factor VIII activity].
    Staritsyna NN; Shanskaia AI; Papaian LP; Ivanova RP
    Klin Lab Diagn; 2011 May; (5):31-3. PubMed ID: 21786611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ADAMTS13 content in plasma-derived factor VIII/von Willebrand factor concentrates.
    Peyvandi F; Mannucci PM; Valsecchi C; Pontiggia S; Farina C; Retzios AD
    Am J Hematol; 2013 Oct; 88(10):895-8. PubMed ID: 23813910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developing rDNA products for treatment of hemophilia A.
    Kaufman RJ
    Trends Biotechnol; 1991 Oct; 9(10):353-9. PubMed ID: 1367761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is the determination of AHF activity feasible for individual cryoprecipitates?
    Frommel D; de Angulo MR
    Vox Sang; 1975; 29(3):228-30. PubMed ID: 1136334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of factor VIII and other coagulation factors by the thioredoxin system.
    Savidge G; Carlebjörk G; Thorell B; Hessel B; Holmgren A; Blombäck B
    Thromb Res; 1979; 16(5-6):587-99. PubMed ID: 316583
    [No Abstract]   [Full Text] [Related]  

  • 12. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
    Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
    Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of 'single donor' factor VIII from plasma exchange donation.
    McLeod BC; Scott JP
    JAMA; 1984 Nov; 252(19):2726-9. PubMed ID: 6436520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individualization of Factor VIII dosage.
    Messori A; Longo G; Morfini M; Donati-Cori G; Matucci M; Ruffo S; Tendi E; Vannini S
    J Clin Hosp Pharm; 1984 Jun; 9(2):95-103. PubMed ID: 6430968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factor VIII concentrate prepared from blood donors stimulated by intranasal administration of a vasopressin analogue.
    Mikaelsson M; Nilsson IM; Vilhardt H; Wiechel B
    Transfusion; 1982; 22(3):229-33. PubMed ID: 6806950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factor VIII concentrate-responsive thrombocytopenia, hemolytic anemia, and nephropathy. Evidence that factor VIII:von Willebrand factor is involved in its pathogenesis.
    Hara T; Kitano A; Kajiwara T; Kondo T; Sakai K; Hamasaki Y
    Am J Pediatr Hematol Oncol; 1986; 8(4):324-8. PubMed ID: 3099591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Principles of in vivo recovery and survival studies of VIII:C.
    Allain JP
    Scand J Haematol Suppl; 1984; 41():123-30. PubMed ID: 6440278
    [No Abstract]   [Full Text] [Related]  

  • 18. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A.
    Hsu HC; Chen YF; Ho CH
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 Jul; 62(7):450-4. PubMed ID: 10418180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calculations of factor VIII in vivo recovery and half-life.
    Kjellman H
    Scand J Haematol Suppl; 1984; 40():165-74. PubMed ID: 6433448
    [No Abstract]   [Full Text] [Related]  

  • 20. von Willebrand disease: treatment with or without factor VIII?
    Konkle BA
    J Thromb Haemost; 2007 Jun; 5(6):1113-4. PubMed ID: 17590904
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.